Nuwellis announces peer-reviewed publication of clinical trials analysis advocating the use of ultrafiltration for heart failure patients resistant to diuretics

Minneapolis, march 21, 2023 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option for acute decompensated heart failure (adhf) patients who are resistant to diuretics or who have a history of multiple hospitalizations for fluid overload. the publication highlights the scale of clinical burden: “adhf has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1
NUWE Ratings Summary
NUWE Quant Ranking